{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.1","upperLimit":"37","value":"21"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"description":"Chronic Graft Versus Host Disease (GVHD) is assessed using the National Institutes of Health (NIH) consensus criteria.","dispersionType":"95% Confidence Interval","groups":[{"description":"All patients receive same therapy\n\nFludarabine: 30 mg/m2/day IV x 6 days\n\nMelphalan: 100 mg/m2/day IV x 1 day\n\nTotal Body Radiation: 200 cGy on Day 0\n\nCord Blood: 2 cord blood units IV","id":"OG000","title":"Fludarabine/Melphalan/TBI"}],"paramType":"NUMBER","populationDescription":"The two participants found to be ineligible after being consented and registered were excluded from the analysis.","reportingStatus":"POSTED","timeFrame":"From the time of transplantation until the time of chronic GVHD onset, up to 1 year","title":"The Rate of Chronic GVHD","type":"SECONDARY","unitOfMeasure":"percentage of participants"}